Application of Multi-omics Analysis in Thoracic Cancer Immunotherapy

Know about the book -

Application of Multi-omics Analysis in Thoracic Cancer Immunotherapy is written by Attila Szöllősi and published by Frontiers Media SA. It's available with International Standard Book Number or ISBN identification 2832556868 (ISBN 10) and 9782832556863 (ISBN 13).

Based on statistical data provided by the World Health Organization, cancer is widely acknowledged as the foremost contributor to global mortality and persists as a significant concern in the contemporary era. In recent times, immunotherapy has been demonstrated as an efficacious approach in diverse advanced solid tumors, especially in thoracic tumors, consequently emerging as a prominent area of focus in the investigation of antitumor pharmaceuticals. The utilization of immunotherapy directed towards programmed death ligand-1 (PD-L1) and programmed cell death protein-1 (PD-1) has emerged as a valid approach, resulting in substantial enhancements in both disease-free and overall survival rates among cancer patients. Moreover, applications of multi-omics analyses in thoracic tumors have made great progress. However, it also ushered in new challenges. Certain subtypes of thoracic cancer have been identified as immune-quiescent tumors, indicating that only a limited number of patients would derive benefits from immunotherapy while also experiencing a high incidence of severe adverse events. Besides, multi-omics analyses reveal patterns of drug resistance and relapse in the treatment of thoracic tumors, which help us identify the molecular mechanisms that lead to drug resistance and provide clues for overcoming it. Meanwhile, exploring the role of the tumor microenvironment (TME) in the development and metastasis of thoracic tumors can help us better understand the potential mechanisms of tumor spread and find approaches to intervene.